LSTA

Lisata Therapeutics Inc

NASDAQ

Add Alert

LSTA

Lisata Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

TheFinalCD PremiumMember

09/15/22 10:20 AM

Post #3,108

Re: #3,104: @tedgoeseast - It going through the roof right now I

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169956690

subslover

09/15/22 9:20 AM

Post #3,107

Re: #3,105: @subslover - Did they change the ticker?tia

Never mind I see they did change the ticker and wow great job. CUDOS to you!

tedgoeseast Free

09/15/22 9:20 AM

Post #3,106

Re: #3,105: @subslover - Did they change the ticker?tia

The ticker it is LSTA get on etrade market castor that is what I am on

subslover

09/15/22 9:17 AM

Post #3,105

Re: #3,102: @tedgoeseast - It shows 615000 premarket on etrade market castor

Did they change the ticker?tia

tedgoeseast Free

09/15/22 9:17 AM

Post #3,104

Re: #3,103: @TheFinalCD - CONGRAT$

It going through the roof right now I left 5000 on the table who knew it was going over 9.00 wow volume at over 627000 now premarket

TheFinalCD PremiumMember

09/15/22 9:16 AM

Post #3,103

Re: #3,099: @tedgoeseast - Wow I got up this morning and it

CONGRAT$

tedgoeseast Free

09/15/22 9:15 AM

Post #3,102

Re: #3,101: @subslover - But the stock shows 0 trades pre mkt???

It shows 615000 premarket on etrade market castor and it over 9.00 a share now wow

subslover

09/15/22 9:05 AM

Post #3,101

Re: #3,100: @tedgoeseast - Clbs my second best play this week wow!!

But the stock shows 0 trades pre mkt???

tedgoeseast Free

09/15/22 8:56 AM

Post #3,100

Re: #3,098: @subslover - You're absolutely correct. I will keep this on watch.

Clbs my second best play this week wow!! When everyone was saying it was tanking big time sold this morning for a nice Gain

tedgoeseast Free

09/15/22 8:32 AM

Post #3,099

Re: #3,097: @TheFinalCD - lately everything is a pnd, they push it

Wow I got up this morning and it was over 7.50 I called etrade and they put my sell order through I just made 2400.00 profit when everyone even moonmarket said it was a bad trade for him ,I bought at .40 yesterday 7.50is like selling it for .60 at the old share structure

subslover

09/14/22 8:12 PM

Post #3,098

Re: #3,097: @TheFinalCD - lately everything is a pnd, they push it

You're absolutely correct. I will keep this on watch.

TheFinalCD PremiumMember

09/14/22 3:55 PM

Post #3,097

Re: #3,093: @subslover - Yea, nothing surprises me

lately everything is a pnd, they push it up too high and short it back

with some exceptions, that have a few day run

tedgoeseast Free

09/14/22 12:04 PM

Post #3,096

Re: #3,095: @PStockPickz - Merger news this morning mixed with the r/s

I have been reading all about it on OTC site and stock twits I put a bid in for .385 just for the fun of it

PStockPickz Free

09/14/22 11:54 AM

Post #3,095

Re: #3,094: @tedgoeseast - YOU BOUGHT AT .63 IT WAS JUST AT .385

Merger news this morning mixed with the r/s is why I bought. Took loss and keeping it on radar for reversal

tedgoeseast Free

09/14/22 10:33 AM

Post #3,094

Re: #3,088: @PStockPickz - Snagged 63s

YOU BOUGHT AT .63 IT WAS JUST AT .385

subslover

09/14/22 10:29 AM

Post #3,093

Re: #3,092: @PStockPickz - Looks like a group wacked out to chase

Yea, nothing surprises me

PStockPickz Free

09/14/22 10:27 AM

Post #3,092

Re: #3,090: @subslover - I didn't get the memo. lol

Looks like a group wacked out to chase another ticker

krisc62

09/14/22 10:26 AM

Post #3,091

Watching for bounce from 52 WL

subslover

09/14/22 9:45 AM

Post #3,090

Re: #3,089: @PStockPickz - Maybe someone didn't get the memo that r/s

I didn't get the memo. lol

PStockPickz Free

09/14/22 9:40 AM

Post #3,089

Re: #3,087: @subslover - LMAO!

Maybe someone didn't get the memo that r/s plays are hot right now haha

PStockPickz Free

09/14/22 9:31 AM

Post #3,088

Re: #3,087: @subslover - LMAO!

Snagged 63s

subslover

09/14/22 9:17 AM

Post #3,087

Re: #3,086: @TheFinalCD - LOLme2

LMAO!

TheFinalCD PremiumMember

09/14/22 9:16 AM

Post #3,086

Re: #3,085: @subslover - This is a very unusual year with all

LOLme2

subslover

09/14/22 9:15 AM

Post #3,085

Re: #3,084: @TheFinalCD - post RS plays are HOT **CLBS* +Merger

This is a very unusual year with all the R/S working out! Scratching my bald head!

TheFinalCD PremiumMember

09/14/22 9:11 AM

Post #3,084

Re: #3,082: @subslover - Merger in progress

post RS plays are HOT **CLBS* +Merger

adtx nrbo

PStockPickz Free

09/14/22 9:11 AM

Post #3,083

Re: #3,082: @subslover - Merger in progress

Yep double whammy r/s and merger. Surprised this isn't getting more attention

subslover

09/14/22 9:04 AM

Post #3,082

Re: #3,080: @conix - Dawson James - Caladrius (CLBS) - Delays, Delays

Merger in progress

PStockPickz Free

09/14/22 9:03 AM

Post #3,081

R/s after the close. Could be another big runner

conix

12/12/21 9:58 PM

Post #3,080

Re: #3,079: @Roadtojourney - Got new bagholders pos imo

Dawson James - Caladrius (CLBS) - Delays, Delays & delays + Burning Cash

Caladrius has fallen to $0.90 from $1.61 (2.15.21) when we wrote "Dam the Shareholders Full Speed Ahead", commenting on the highly dilutive capital raise. Revisiting the story, we see little progress. Caladrius reported 3Q21 results spending $7M in the quarter, steadily whittling down its $100M in cash balance but to what end? We note multiple delays across previously promoted programs such as CLI in Japan, now suspended.
Click here for the full report

HONDERA (CLBS12) – Suspended for CLI in Japan –This was planned as a small Phase 2 study, an interventional, open-label, proof-of-concept (POC) trial planned for two centers, but the company had problems finding patients, blaming COVID. Caladrius now says the program is suspended until a Japanese partner is identified. We remain skeptical and see this program as "dead."

XOWNA (CLBS16) – Enrollment has Slowed: The product is currently being evaluated in a P2b study in patients with CMD and without obstructive coronary artery disease. Patient enrollment is behind schedule, so the company has been expanding the number of sites and modifying the study protocol. These protocol amendments were implemented in the latter part of the quarter. We see these as "red flags."

Management was Pushing the CD34+ cells as a COVID Play – This appears to have fizzled out. Is anyone surprised? What's the Problem? On just about every level, we find management's explanations across multiple programs as lacking. Management seems to lack an understanding of 1. the competitive environment. Multiple off-the-shelf, allogeneic companies are already treating COVID patients but on ventilators and potentially earlier, and recent failures of other cell therapies in COVID due to improved standard of care. 2. For example, in COVID, using cells to ameliorate the after-effects of ventilator therapy for COVID patients is a great idea, BUT a) harvesting cells from these patients is not ideal; b) how do you measure how effective your treatment is? For NORDA, we see a POC trial as a $65M and multi-year investment. What size trial is needed to measure the effect versus standard of care? 3. Caladrius's autologous therapy is very late in the field.

Valuation. For Caladrius, we previously lowered our rating to Neutral from Buy (March 2020) and removed our price target. Our model uses our highest discount rate of 30% in our free cash flow to the Firm (FCFF), discounted EPS, and Sum of the Parts (SOP) models. Our models go out to 2029 and have been updated for the recent dilution. The company now has a negative enterprise value, but we believe that won't last as its likely management will now be on a spending spree. Spending on clinical trials that we feel go nowhere and or looking to make an acquisition. Our bottom-line concern is that Caladrius has, in our opinion, missed the window. Allogenic competitors are advancing now in heart failure, back pain, stroke, CLI, GvHD, and three companies are today treating COVID patients for ARDS

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

Roadtojourney Free

03/03/21 3:20 PM

Post #3,079

Got new bagholders pos imo

slow_feet

03/02/21 12:52 PM

Post #3,078

SI as of 2/12/21

2/12/2021 1,450,000 shares
1/29/2021 2,930,000 shares
1/15/2021 127,600 shares
12/31/2020 130,000 shares
12/15/2020 130,000 shares

slow_feet

02/24/21 7:40 PM

Post #3,077

Four funds have new positions as of 2/12/21: https://whalewisdom.com/stock/nbs-2

CINCY_4MONEY Free

02/17/21 9:53 AM

Post #3,076

this stock is hot. they have a 9 a share 1st year target we will get there soon

slow_feet

02/12/21 2:37 PM

Post #3,075

Opened a cr*p-load of April Calls in the AM.

C'mon 7!

ClayTrader Free

01/20/21 4:21 PM

Post #3,074

* * $CLBS Video Chart 01-20-2021 * *

Link to Video - click here to watch the technical chart video

hotonthemoney Free

01/20/21 1:53 PM

Post #3,073

Why Caladrius Biosciences Is Soaring Today

hotonthemoney Free

01/20/21 1:11 PM

Post #3,072

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Carioca

01/20/21 10:14 AM

Post #3,071

weregoingherecscw

Ruffieruff Free

01/20/21 10:01 AM

Post #3,070

Re: #3,066: @Ruffieruff - 14PT this morning. Huge move ahead.

Out as well. Pulled a profit so all good. Gltu

wickerman

01/20/21 9:58 AM

Post #3,069

Re: #3,049: @wickerman - $CLBS quietly add low don't look at it

$CLBS out core $4.05 will revisit..patience + DD forever

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

https://www.biospace.com/article/releases/caladrius-biosciences-treats-first-patient-in-the-phase-2b-freedom-trial-of-clbs16-for-the-treatment-of-coronary-microvascular-dysfunction/#:~:text=(Nasdaq%3A%20CLBS)%20(%E2%80%9C,dysfunction%20(%E2%80%9CCMD%E2%80%9D)%20at

Docstemcell2020 Free

01/20/21 9:18 AM

Post #3,068

Nice

AlphaStockNews Free

01/20/21 7:44 AM

Post #3,067

$CLBS is squeezing the shorts out of their positions following an announcement of a patient treated in a Phase 2b trial. https://cnafinance.com/clbs-stock-caladrius-biosciences-squeezes-shorts/

Ruffieruff Free

01/20/21 7:38 AM

Post #3,066

14PT this morning. Huge move ahead.

Ruffieruff Free

12/14/20 9:32 AM

Post #3,065

Re: #3,058: @wickerman - $CLBS aren't those $1.50-$1.60 buys sitting pretty now? Patience.

Figured you were long out. Now this bomb confirms it.

Ruffieruff Free

11/17/20 7:44 PM

Post #3,064

Re: #3,058: @wickerman - $CLBS aren't those $1.50-$1.60 buys sitting pretty now? Patience.

Have you sold and moved on. Very quiet around here.

Ruffieruff Free

10/21/20 1:36 PM

Post #3,063

Re: #3,058: @wickerman - $CLBS aren't those $1.50-$1.60 buys sitting pretty now? Patience.

Falling apart here. Are we do any updates anytime soon?

Ruffieruff Free

09/30/20 4:20 PM

Post #3,062

Re: #3,058: @wickerman - $CLBS aren't those $1.50-$1.60 buys sitting pretty now? Patience.

How much patience does one need. We are going sideways and it’s not too much fun.

Swimmingly Free

09/18/20 6:55 PM

Post #3,061

Re: #3,060: @Ruffieruff - Unfortunately not looking so hot for us who

Bought a few more cheapies today. Just have to be patient with this one.

Ruffieruff Free

09/18/20 6:45 PM

Post #3,060

Re: #3,058: @wickerman - $CLBS aren't those $1.50-$1.60 buys sitting pretty now? Patience.

Unfortunately not looking so hot for us who bought in much higher.

Swimmingly Free

09/16/20 1:40 PM

Post #3,059

Re: #3,058: @wickerman - $CLBS aren't those $1.50-$1.60 buys sitting pretty now? Patience.

They sure are. GL

Older

Lisata Therapeutics Inc (LSTA)

Followers	84	Posters	267
Posts (Today)	0	Posts (Total)	3108
Created	03/08/07	Type	Free
Moderators

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).

www.caladrius.com